Midostaurin CAS 120685-11-2

Product Description:

Product Name: Midostaurin CAS NO: 120685-11-2

Synonyms:

4'-N-benzoylstaurosporine;

PKC412,[9S-(9α,10β,11β,13α)]-N-(2,3,10,11,12,13-Hexahydro-10-metho-xy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide;

Cgp 41 251;

Chemical & Physical Properties:

Appearance: Tan solid

Assay :≥99.0%

Density: 1.46g/cm3

Refractive Index: 1.76

Storage Condition: Store at 2-8℃

Solubility: Soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml), 100% ethanol (2.5 mg/ml), and DMF (20 mg/ml).

Safety Information:

Hazard Code: T

Risk Statements: R36/37/38

HS Code: 29329990

Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus, and is active in patients with mutations of CD135 (FMS-like tyrosine kinase 3 receptor, FLT3).

After successful Phase II clinical trials, a Phase III trial for AML has started in 2008. It is testing midostaurin in combination with daunorubicin and cytarabine. In another trial, the substance has proven ineffective in metastatic melanoma.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.